Bristol Myers Squibb revenue
Bristol Myers Squibb's revenue was $48.19bn in fiscal 2025, down 0.2% on the year before. Since fiscal 2009 ($18.81bn) it has grown at a compound 6.1% a year. Over the last twelve months it was $50.03bn.
Revenue history
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.8 | 19.5 | 21.2 | 17.6 | 16.4 | 15.9 | 16.6 | 19.4 | 20.8 | 22.6 | 26.1 | 42.5 | 46.4 | 46.2 | 45.0 | 48.3 | 48.2 | 50.0 |
| Growth on the year before | — | +3.6% | +9.0% | −17.1% | −7.0% | −3.1% | +4.3% | +17.3% | +6.9% | +8.6% | +15.9% | +62.6% | +9.1% | −0.5% | −2.5% | +7.3% | −0.2% | — |
| Gross profit | 13.7 | 14.2 | 15.6 | 13.0 | 11.8 | 11.9 | 12.7 | 14.5 | 14.7 | 16.1 | 18.1 | 30.7 | 36.4 | 36.0 | 34.3 | 34.3 | 34.3 | 34.6 |
| Gross margin | 72.7% | 72.9% | 73.6% | 73.8% | 71.8% | 75.2% | 76.4% | 74.5% | 70.7% | 71.3% | 69.1% | 72.3% | 78.6% | 78.0% | 76.2% | 71.1% | 71.1% | 69.2% |
Where the revenue comes from
| Line of business | Revenue | YoY |
|---|---|---|
| Sales Revenue Gross | $88.1B | ▲ 5.3% |
| Net Product Sales | $46.8B | 0.0% |
| Growth Brands | $26.4B | ▲ 17.0% |
| Legacy Brands | $21.8B | ▼ 15.4% |
| Eliquis | $14.4B | ▲ 8.3% |
| Opdivo | $10B | ▲ 8.0% |
| Orencia | $3.7B | ▲ 0.6% |
| Revlimid | $3B | ▼ 48.9% |
| Yervoy | $2.9B | ▲ 14.6% |
| Pomalyst Imnovid | $2.7B | ▼ 22.9% |
| Reblozyl | $2.3B | ▲ 31.2% |
| Other Growth Brands | $1.9B | ▲ 17.1% |
| Alliance and Other Revenues | $1.4B | ▼ 5.5% |
| Breyanzi | $1.4B | ▲ 81.8% |
| Opdualag | $1.2B | ▲ 27.7% |
| Camzyos | $1.1B | ▲ 77.4% |
| Otherrevenues | $992M | ▼ 4.9% |
| Other Legacy Brands | $798M | ▼ 13.7% |
| Zeposia | $577M | ▲ 1.9% |
| Sprycel | $493M | ▼ 61.7% |
| Alliance Revenues | $447M | ▼ 6.7% |
| Abecma | $427M | ▲ 5.2% |
| Abraxane | $368M | ▼ 57.9% |
| Sotyktu | $291M | ▲ 18.3% |
| Opdivo Ovantig | $238M | — |
| Krazati | $205M | ▲ 62.7% |
| Cobenfy | $155M | ▲ 1450.0% |
These categories overlap or exclude eliminations, so shares aren't shown.
| Region | Revenue | Share | YoY |
|---|---|---|---|
| United States | $33.3B | 69.1% | ▼ 2.4% |
| Outside the US | $13.8B | 28.7% | ▲ 4.8% |
| Other Region | $1.1B | 2.3% | ▲ 9.1% |
From Bristol Myers Squibb's 10-K filed February 11, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Bristol Myers Squibb | $50.03bn | 4.2% | 3.6% |
| Novo Nordisk A S | $46.82bn | 11.1% | — |
| GSK plc | $43.09bn | 7.5% | — |
| Astrazeneca PLC | $58.74bn | 8.6% | — |
| Pfizer | $63.70bn | -0.2% | -7.0% |
| Merck & Co. | $66.57bn | 4.6% | 4.5% |
Compare with peers
Head to head: BMY vs NVOBMY vs GSKAZN vs BMYBMY vs PFE
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies